Parkinson's disease/Parkinson syndromes—therapy: Levodopa

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 249 KB
• Volume: 7
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.870070543

✦ Synopsis

Three patients with Parlcinson's disease, optimally treated with levodopdcabidopa (LDKD) tablets, but experiencing severe motor fluctuations, were administered a solution of levodopd carbidopalascorbic acid (LCAS) orally at intervals ranging from 30 to 60 minutes. Patients were rated half-hourly to document akinesia and dyskinesia. Compared to optimal therapy with LD/CD tablets, patients experienced a significant reduction in percent of total observed time with dysfunctional akinesia (27 +/-12% versus 5 +/-8.7%). reduction in dysfunctional dyskinesia (29 +/-9.7% versus 5 +/-8.7%) and had increased functional "on" time (43 +/-13% versus 90 +/-17%) while on LCAS. Use of LCAS allowed easier titration of Ievodopa dosage and offered a more predictable response than LD/CD tablets. Patients found preparation and oral consumption of the LCAS solution easy and inexpensive. These findings suggest that LCAS may be a practical therapeutic alternative for patients whose motor fluctuations fail to respond to optimal therapy with LD/CD tablets. A Positive Pharmamkinetic Interacticn Eetbeen Benzotrorole of Carbid-. pine bsylate and Lwodopa. ' Ihe C. sHnpaiO*;-A. Castro 4 d d S * * ; M.M. € b ~a * ; M. Passarinho*; v. ma.

the biovailabllity of I e w was investigated in a dxlble-blind, cross-ove~, ccntrolled study. A sinqle dose of Benzatropine besylate (2n-q) was dde3 to a dose of Carbidopa/levcdopa (ZS/lOO) or t o Larodopa alone (50chng).